Antibody Stability Testing via IdeS Enzymatic Cleavage

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for analyzing therapeutic monoclonal antibodies face challenges in efficiently detecting and separating IgG antibodies and their fragments due to complex degradation processes, such as oxidation, deamidation, and proteolytic cleavage, which affect their activity and immunogenicity, and existing chromatographic methods struggle with resolving diverse chromatographic and electrophoretic bands.

Innovation Solution

A method involving sequential incubation of a sample containing IgG antibodies with the IgG-specific cysteine protease IdeS, N-glycosidase F, trichloroethyl phosphate, and formic acid, followed by coupled liquid chromatography and mass spectrometry to detect intact antibodies and fragments, optimizing enzyme:antibody ratios and incubation conditions for effective digestion and analysis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Volume of stationary object

If RP-HPLC methods are applied to separate antibody species, then separation capability is improved, but analysis complexity and difficulty increase due to simultaneous presence of various modifications

Engineering Contradiction:
Improveseparation capabilityVSAvoidanalysis complexity
Core Design Contradiction:
Volume of stationary objectVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the intact antibody into smaller fragments through enzymatic cleavage by IdeS protease. This generates a defined set of peptide fragments (Fab and Fc regions) that can be analyzed separately by mass spectrometry, avoiding the complexity of separating all possible modified forms of the intact antibody through chromatography.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent replaces the mechanical separation system (RP-HPLC chromatography) with a biochemical system (enzymatic digestion followed by mass spectrometry). Instead of physically separating antibody species through chromatographic columns, the method uses IdeS protease to cleave antibodies into characteristic fragments whose masses are measured and identified by mass spectrometry, providing simpler and more definitive separation and identification.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Manufacturing precision

If IdeS protease is used to cleave IgG antibodies, then specific fragmentation is improved, but complete digestion may not be achieved without optimization of enzyme:antibody ratios and incubation conditions

Engineering Contradiction:
Improvespecific fragmentationVSAvoiddigestion completeness
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The patent applies parameter changes by systematically optimizing the enzyme:antibody ratio and incubation conditions to achieve complete digestion. By adjusting these parameters, the method ensures that IdeS protease fully cleaves all IgG antibodies in the sample into the expected Fab and Fc fragments, eliminating any intact antibody or partially digested species that would complicate the mass spectrometry analysis.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for precise detection and separation of IgG antibodies and their fragments, enhancing the analysis of stress-induced degradation products and improving the sensitivity and resolution of mass spectrometry measurements, thereby ensuring the quality and safety of protein therapeutic agents.

Implementation Method 1

The cysteine endoprotease IdeS (Immunoglobulin degrading enzyme S) from the human pathogen Streptococcus pyogenes which is also referred to as Mac-1 or sib-38, is a cysteine protease that specifically cleaves the heavy chain of antibodies of the immunoglobulin G type (IgG). IdeS cleaves human IgG (class G immunoglobulin) between the amino acids 236 and 237

Methodology Applied
Scientific EffectProteolytic cleavage: Hydrolysis

Implementation Method 2

N-glycosidase F

Methodology Applied
Scientific EffectGlycosidase hydrolysis: Hydrolysis

Implementation Method 3

the reducing agent trichloroethyl phosphate and formic acid

Methodology Applied
Scientific EffectDisulfide bond reduction: Reduction

Data Source

PatentEP2225273B1Stability testing of antibodies
Publication Date: 2012.05.23 ROCHE GLYCART AG
  • EP2225273B1 patent drawingFigure 1a~1b
  • EP2225273B1 patent drawingFigure 2
  • EP2225273B1 patent drawingFigure 3

AI summary

Antibodies are biological macromolecules which may be subject to modification and degradation processes. A new LC/MS-based method for separating and characterizing antibody-specific degradation products is described in the present application which comprises an enzymatic digestion step to cleave the heavy chain using the enzyme IdeS.